Which one is better, Ixazomib or Lenalidomide?

Ixazomib and lenalidomide are two different drugs used to treat multiple myeloma. Their effects vary depending on individual differences, but their mechanisms of action, side effects, usage and dosage are different. Because every patient's situation is different, the best option may depend on several factors, such as the patient's specific condition, doctor's recommendations, and personal preference.

Ixazomib is an oral proteasome inhibitor that inhibits tumor growth by blocking proteasome function in cancer cells. It is often used in combination with other drugs, such as lenalidomide and dexamethasone, and is administered in the form of oral capsules. Lenalidomide is an immunomodulator that inhibits the growth of cancer cells through multiple mechanisms. It is often used with other drugs such as ixazomib and dexamethasone and can be taken orally or intravenously. While taking ixazomib, patients need to be regularly evaluated and monitored by their physician to ensure the safety and effectiveness of the treatment. If the patient's condition is effectively controlled and gradually improving, the doctor may adjust the treatment plan, reduce the dose, or extend the treatment interval.

The original drug of Ixazomib has been launched in China and is included in Class B medical insurance. The price of common capsule preparations may be more than 10,000 yuan per box, which is relatively expensive. The price of the original drug of ixazomib sold overseas is more than 10,000 US dollars per box (the price may fluctuate due to the exchange rate). Ixazomib Generic drugs are also produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 4mg*3 tablets produced by a Laos pharmaceutical factory may be less than 1,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.